CRSP vs EDIT
CRSP and EDIT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | CRSPCRISPR THERAPEUTICS AG | EDITEditas Medicine, Inc. |
|---|---|---|
| Market cap | $4.65B | $261.41M |
| P/S | 1325.8x | 6.5x |
| Revenue growth (YoY) | -90.6% | 25.4% |
| Earnings growth (YoY) | -58.8% | 32.5% |
| EBIT margin | -18933.6% | -394.9% |
| ROE | -32.1% | -3631.1% |
| ROIC | -33.6% | — |
| 1y total return | -16.3% | +6.6% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: CRSP vs EDIT
| 지표 | CRSP | EDIT |
|---|---|---|
| 최종 가치 | $34.2K | $1.9K |
| 총수익률 | +242.5% | -80.8% |
| CAGR | +13.4% | -15.5% |
| 변동성 | 64.2% | 84.4% |
| 샤프 | 0.45 | 0.16 |
| 소르티노 | 0.70 | 0.25 |
| 최대 낙폭 | -85.1% | -98.9% |
공통 거래일 2457일 기준, 2016-10-19 → 2026-07-30 · 무위험수익률 3.83% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)